Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024.

Data on the Guardant Reveal minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360 for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity platform for response monitoring in advanced non-small cell lung cancer (NSCLC).

“Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types,” said Craig Eagle, M.D., chief medical officer at Guardant Health. “We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care.”

Complete list of Guardant Health and collaborator presentations at ESMO 2024

Abstract	Title (Hall 6, unless otherwise noted)	Product
Saturday, September 14 | 9:00 - 17:00
1295P	EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI	Guardant Infinity
Sunday, September 15 | 9:00 - 17:00
127P	Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors	Guardant 360
Monday, September 16 | 9:00 - 17:00
418P	Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer